Nephrology
RCT | Heterogeneity in blood pressure response to 4 antihypertensive drugs
17 Apr, 2023 | 13:14h | UTCHeterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial – JAMA (free for a limited period)
News Release: Personalized blood pressure treatment more effective – Uppsala University
RCT | Methylprednisolone pulse followed by oral prednisone vs. oral prednisone alone in sarcoidosis tubulointerstitial nephritis
17 Apr, 2023 | 12:58h | UTCEfficacy and safety of methylprednisolone pulse followed by oral prednisone vs. oral prednisone alone in sarcoidosis tubulointerstitial nephritis: a randomized, open-label, controlled clinical trial – Nephrology Dialysis Transplantation (free for a limited period)
Review | Why is intradialytic hypotension the commonest complication of outpatient dialysis treatments?
5 Apr, 2023 | 13:28h | UTC
What is acute kidney injury? A visual guide
4 Apr, 2023 | 14:02h | UTCWhat is acute kidney injury? A visual guide – Nature
Review | Prolonged intermittent kidney replacement therapy
3 Apr, 2023 | 13:39h | UTCProlonged Intermittent Kidney Replacement Therapy – Clinical Journal of the American Society of Nephrology (free for a limited period)
Commentary on Twitter
Kidney replacement therapy (KRT) is a vital, supportive treatment for patients with critical illness and severe AKI. This Review discusses the option of prolonged intermittent KRT in the management of patients with kidney failure in the ICU https://t.co/jPHVLRnoqJ@VijayanMD pic.twitter.com/4oWJ6IDR4C
— CJASN (@CJASN) September 30, 2022
RCT | Sparsentan reduces proteinuria in patients with IgA nephropathy
3 Apr, 2023 | 13:35h | UTCSparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
PROTECT (Interim results): Sparsentan reduces proteinuria in patients with IgA Nephropathy (IgAN)#ISNWCN ?? #Nephpearls#VisualAbstract by @dakidneydochttps://t.co/ViW9YncwI6 pic.twitter.com/zEGRSY8N3x
— Edgar V. Lerma ?? (@edgarvlermamd) April 1, 2023
Glomerular diseases in pregnancy: pragmatic recommendations for clinical management
3 Apr, 2023 | 13:29h | UTC
Review | Evaluation and management of hypernatremia in adults
30 Mar, 2023 | 14:20h | UTC
Cohort Study | Evaluating 5 creatinine-based formulas for eGFR estimation in older patients
29 Mar, 2023 | 13:12h | UTC
Commentary on Twitter
5 commonly-used creatinine-based equations provided different eGFR estimates in older adults in Sweden. BIS equation outperformed others in predicting 15-year mortality, but its accuracy was reduced in subgroups of low muscle mass and high age. https://t.co/DOJmp4HzZn
— JAMA Network Open (@JAMANetworkOpen) March 23, 2023
Podcast | Pears in primary aldosteronism, mineralocorticoid receptor antagonists, and renovascular hypertension
29 Mar, 2023 | 13:07h | UTC
Study shows increased bleeding complications in ESKD patients undergoing AF ablation
24 Mar, 2023 | 13:09h | UTCSummary: The study analyzed 347 procedures in 307 patients with end-stage kidney disease (ESKD) undergoing atrial fibrillation (AF) catheter ablation in 12 referral centers in Japan.
Despite a vast majority of patients having subtherapeutic international normalized ratio (INR) values during the peri-procedural period, 35 patients (10%) experienced major complications, with the majority being major bleeding events (19 patients; 5.4%), including 11 cases of cardiac tamponade (3.2%). There were also two peri-procedural deaths (0.6%), both related to bleeding events. A pre-procedural INR value of 2.0 or higher was identified as the only independent predictor of major bleeding.
Current peri-procedural anticoagulation guidelines state that patients undergoing AF ablation should be under therapeutic anticoagulation throughout the peri-procedural period. The findings of this study suggest that these guidelines may not be appropriate for ESKD patients undergoing the procedure, and the role of peri-procedural anticoagulation in this population should be further investigated.
Commentary on Twitter
Peri-procedural anticoagulation in patients with end-stage kidney disease undergoing #afib ablation ? despite undertreatment with warfarin, the rate of haemorrhagic complications is high! https://t.co/3W8gEtZYdy#kidney #afib #anticoagulation #ablation #cardiotwitter #europace pic.twitter.com/vI27UeIpRf
— European Society of Cardiology Journals (@ESC_Journals) March 16, 2023
Review | Unapparent systemic effects of regional anticoagulation with citrate in continuous renal replacement therapy
24 Mar, 2023 | 13:04h | UTC
Single-arm study | Inaxaplin reduces proteinuria in patients with APOL1 variants and focal segmental glomerulosclerosis
21 Mar, 2023 | 13:11h | UTCInaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Inaxaplin Reduces Proteinuria in FSGS With APOL1 Variants – Renal & Urology News
Commentary on Twitter
Original Article: Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants https://t.co/QHcvbYEmiz #nephrology #CKD pic.twitter.com/SLspl6Vagn
— NEJM (@NEJM) March 17, 2023
Perspective | How I prescribe prolonged intermittent renal replacement therapy
14 Mar, 2023 | 13:26h | UTCHow I prescribe prolonged intermittent renal replacement therapy – Critical Care
ISCCM Guidelines on acute kidney injury and renal replacement therapy
13 Mar, 2023 | 14:55h | UTC
Review | Acquired disorders of hypomagnesemia
7 Mar, 2023 | 13:09h | UTCAcquired Disorders of Hypomagnesemia – Mayo Clinic Proceedings
Podcast | Updates in chronic kidney disease
7 Mar, 2023 | 12:51h | UTC#384 Updates in Chronic Kidney Disease with Dr. Joel Topf – The Curbsiders
RCT | Hydrochlorothiazide is not effective for the prevention of kidney-stone recurrence
6 Mar, 2023 | 14:26h | UTCSummary:
This study aimed to assess the effectiveness of hydrochlorothiazide, a thiazide diuretic, in preventing the recurrence of calcium-containing kidney stones. The trial randomly assigned 416 patients with recurrent kidney stones to receive hydrochlorothiazide at a dose of 12.5 mg, 25 mg, or 50 mg once daily, or a placebo once daily, and followed them for a median of 2.9 years.
The results showed that the incidence of kidney stone recurrence did not differ significantly between the hydrochlorothiazide and placebo groups, regardless of the dose. Furthermore, patients who received hydrochlorothiazide were more likely to experience side effects such as hypokalemia, gout, new-onset diabetes mellitus, skin allergy, and a plasma creatinine level exceeding 150% of the baseline level.
Therefore, the effectiveness of hydrochlorothiazide in preventing kidney stone recurrence may be limited, and the common practice of prescribing it for these patients should be reevaluated.
Article: Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence – New England Journal of Medicine (link to abstract – $ for full-text)
Video Summary: Hydrochlorothiazide and Kidney-Stone Recurrence | NEJM
Commentary: Hydrochlorothiazide and Prevention of Kidney Stones – NEJM Resident 360
SR | Interventions for preventing and treating kidney disease in IgA vasculitis
3 Mar, 2023 | 13:47h | UTCInterventions for preventing and treating kidney disease in IgA vasculitis – Cochrane Library
RCT | Endovascular ultrasound renal denervation is modestly effective in the treatment of hypertension
1 Mar, 2023 | 14:11h | UTCSummary: The RADIANCE II randomized clinical trial investigated the efficacy and safety of endovascular ultrasound renal denervation in patients with hypertension without the influence of antihypertensive medications. The trial enrolled 224 patients who were withdrawn from such medications and randomly assigned to receive either ultrasound renal denervation or a sham procedure. Results showed that ultrasound renal denervation reduced ambulatory systolic blood pressure by 6.3 mmHg on average at 2 months, compared to the sham procedure, without any reported adverse events. While these findings suggest that ultrasound renal denervation may be modestly effective in the treatment of hypertension, the short-term follow-up period limits the generalizability of these results to daily practice. Additionally, the clinical relevance of a procedure that reduces blood pressure only after withdrawing blood pressure medications should be considered.
Article: Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Is There a Role for Renal Denervation in the Treatment of Hypertension? – JAMA Cardiology (free for a limited period)
Pooled analysis of 3 sham-controlled trials on ultrasound renal denervation for patients with hypertension
1 Mar, 2023 | 14:10h | UTCSummary: The article reports a patient-level pooled analysis of 3 randomized clinical trials that aimed to determine the effectiveness and safety of ultrasound renal denervation (uRDN) in reducing blood pressure (BP) compared to a sham procedure. The analysis included 506 patients with varying severities of hypertension and found that uRDN was modestly effective in reducing daytime ambulatory systolic BP at 2 months compared to the sham procedure, with a mean difference of 5.9 mmHg. One of the limitations of this analysis is that its findings are restricted to a 2-month follow-up. Additional follow-up from the included trials will be required to examine the durability of the effect and safety data.
Editorial: Is There a Role for Renal Denervation in the Treatment of Hypertension? – JAMA Cardiology (free for a limited period)
M-A | Application of enhanced recovery after surgery in partial nephrectomy for renal tumors
28 Feb, 2023 | 13:46h | UTCRelated:
Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines
Consensus Report | Sepsis-associated acute kidney injury
27 Feb, 2023 | 13:05h | UTCSepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup – Nature Reviews Nephrology (if the link is paywalled, try this one)
Commentary on Twitter
A Primer in @DiseasePrimers summarizes the epidemiology, mechanisms, diagnosis and treatment of pre-eclampsia, and discusses patient quality of life and open research questions for this condition. https://t.co/IO3uchSl8b pic.twitter.com/Y7Ij6jmy5a
— Nature Portfolio (@NaturePortfolio) February 25, 2023
Onconephrology 2022: an update
27 Feb, 2023 | 12:58h | UTCOnconephrology 2022: An Update – Kidney360
Related:
Treatment of acute kidney injury in cancer patients – Clinical Kidney Journal
Onconephrology: Update in Anticancer Drug-Related Nephrotoxicity – Nephron
SR | Clinicopathological features of kidney injury related to immune checkpoint inhibitors
27 Feb, 2023 | 12:56h | UTCRelated:
Onconephrology 2022: An Update – Kidney360
Treatment of acute kidney injury in cancer patients – Clinical Kidney Journal
Onconephrology: Update in Anticancer Drug-Related Nephrotoxicity – Nephron